Desmopressin plus anticholinergic combination for primary nocturnal enuresis treatment

Therapeutic effect of desmopressin plus anticholinergics combination as a first line therapy in the treatment of children with primary monosymptomatic nocturnal enuresis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005178

Enrollment

100

Registered

2020-06-29

Start date

2016-01-12

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Anticholinergic drug (propiverine) 5 mg + desmopressin 120 µg for treatment arm, and desmopressin 120 µg alone for control arm. The drugs were administered once/day, for 3 months, per os.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged 6 to 14 years with Primary Monosymptomatic Nocturnal Enuresis

Exclusion criteria

Exclusion criteria: dysuria, urinary frequency (8 or more times per day), decreased voiding (3 or less times per day), urinary incontinence, urgency, strain to void, weak stream, secondary enuresis, gastrointestinal disorder, constipation, narrow angle glaucoma

Design outcomes

Primary

Measure	Time frame
Symptom improvement according to International Children’s Continence Society criteria	—

Secondary

Measure	Time frame
relapse of enuresis	—

Countries

Korea, Republic of

Contacts

Public ContactMyungsun Shim

Hallym University Medical Center

Outcome results